Biologics: other pt 2 Flashcards
ustekinumab MOA
IL-12 and IL-23 antagonist
ustekinumab indications
UC, CD
ustekinumab place in therapy
Induction and maintenance
ustekinumab ADRs
Hypersensitive possible (angioedema or anaphylaxis)
ADAs
Cutaneous cell carcinomas
Possible neurotoxicity
Reversible posterior leukoencephalopathy syndrome
ustekinumab monitoring
TDM possible
Monitor all pts for cutaneous cell carcinoma
monitor closely in patients > 60, with prolonged
immunosuppressant therapy, and with history of phototherapy
risankizumab MOA
Selective IL-23 antagonist
risankizumab indications
UC, CD
risankizumab place in therapy
induction and maintenance of mod-severe disease
risankizumab ADRs
HA
Nasopharnygitis
Arthralgia
Abdominal pain
Anemia
Nausea
Infections
Hypersensitivity
ADAs
Hepatotoxicity
Increase in lipids
risankizumab monitoring
CXR, PPD
Hep B, C
Lipids
LFTs
Renal fnc
S/S of infection
risankizumab pearls
Vaccines necessary
Avoid live vaccines
mirikizumab MOA
IL-23p19 antagonist
mirikizumab indication
UC
mirikizumab place in therapy
induction and maintenance of mod-severe disease
mirikizumab ADRs
HA
Arthralgia
Rash
Injection site reaction
Infections
Upper RTIs
Hypersensitivity
ADAs
Hyepatotoxicity
